| Company Name: |
Musechem |
| Tel: |
+1-800-259-7612 |
| Email: |
info@musechem.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
AltretaMine (hydrochloride) manufacturers
|
| | AltretaMine (hydrochloride) Basic information |
| Product Name: | AltretaMine (hydrochloride) | | Synonyms: | AltretaMine (hydrochloride);Altretamine (RB-1515, WR-95704) hydrochloride;ENT-50852 hydrochloride;Altretamine (RB-1515,WR-95704) HCl;Hemel Hydrochloride;RB-1515 hydrochloride;RB-1515 hydrochloride|||ENT-50852 hydrochloride;WR-95704 hydrochloride|||ENT-50852 hydrochloride|||WR-95704 hydrochloride | | CAS: | 2975-00-0 | | MF: | C9H19ClN6 | | MW: | 246.74036 | | EINECS: | | | Product Categories: | | | Mol File: | 2975-00-0.mol |  |
| | AltretaMine (hydrochloride) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | form | Powder |
| | AltretaMine (hydrochloride) Usage And Synthesis |
| Uses | Altretamine hydrochloride is an alkylating antineoplastic agent. | | in vivo | Altretamine (100, 133 mg/kg, ip.) in combination with Irofulven, increases the antitumor effect in mice bearing MV522 cells[1]. | | References | [1] Kelner MJ, et al. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26. DOI:10.1007/s00280-008-0703-0 |
| | AltretaMine (hydrochloride) Preparation Products And Raw materials |
|